T umor necrosis factor alpha (TNF-α ) is considered to be a major cause of radiculopathy associated with symptomatic lumbar disc herniation.
1 , 2 TNF-α is a critical mediator of nerve root infl ammation, central sensitization, and neuropathic pain that underlie sciatica. 3 -5 Studies using TNF-α inhibitors for the treatment of sciatica have had varying results. 6 -11 These studies predominantly used either intravenous or subcutaneous routes of administration. Because the vertebral disc is poorly vascularized, systemic administration of TNF-α inhibitors would require high doses to achieve efficacy. Thus, localized administration of TNF-α inhibitors may be more benefi cial and may lead to fewer adverse events (AEs).
Etanercept is a recombinant fusion protein of the p75 subunit of the TNF receptor with the Fc component of the human immunoglobulin G1. Studies have demonstrated that patients with sciatica treated with 3 subcutaneous injections Results: Forty-three of the 49 randomized patients completed the study. Patients receiving 0.5-mg etanercept showed a clinically and statistically signifi cant ( P < 0.1) reduction in mean daily WLP compared with the placebo cohort from 2 to 26 weeks for both the per protocol population ( − 5.13 vs . − 1.95; P = 0.066) and the intention-to-treat population ( − 4.40 vs . − 1.84; P = 0.058). Fifty percent of these subjects reported a 100% reduction in WLP 4 weeks post-treatment compared with 0% of subjects in the placebo cohort. Improvements in all secondary outcomes were also observed in the 0.5-mg etanercept cohort. The overall incidence of adverse events was similar in placebo and all etanercept cohorts. Conclusion. Two transforaminal injections of etanercept provided clinically signifi cant reductions in mean daily WLP and worst back pain compared with placebo for subjects with symptomatic LDH. Epidural etanercept may offer patients with sciatica a safe and effective nonoperative treatment.
of etanercept demonstrated a signifi cant decrease in leg and back pain and signifi cant improvements in Oswestry Disability Index (ODI) and Roland Morris Disability Questionnaire compared with historical intravenous steroid controls. 10 Etanercept has also been investigated via direct administration in patients with sciatica. Cohen et al 12 found intradiscal etanercept (0.1-1.5 mg) to be ineffective for the treatment for chronic radicular or discogenic low back pain. However, the same group later found signifi cant improvements in leg and back pain for patients with subacute radiculopathy after epidural administration of etanercept (2-6 mg) compared with placebo. 13 This multicenter randomized, double-blind, placebocontrolled trial was designed to investigate the safety and efficacy of etanercept delivered via the transforaminal epidural route for the treatment of symptomatic lumbosacral disc herniation using an expanded dose range, in an expanded cohort, in a trial with highly structured inclusion and exclusion criteria, carried out in multiple centers.
MATERIALS AND METHODS
This study was conducted between March 2009 and December 2010 at 6 centers in Australia (Royal Adelaide Hospital, Adelaide, South Australia, Australia; Cabrini Medical Centre, Malvern, Victoria, Australia; Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia; Fremantle Hospital, Fremantle, Western Australia, Australia; Metro Spinal Clinic, Melbourne, Victoria, Australia; and Royal North Shore Hospital, Sydney, New South Wales, Australia). The human research ethics committees of all participating centers approved the study protocol. All subjects provided written informed consent.
Subjects
Subjects between the ages of 18 and 70 years, with the current diagnosis of lumbosacral radicular pain of 6 to 26 weeks duration secondary to lumbar disc herniation confi rmed by radiological means with a mean pain score of 5/10 or more for average leg pain (ALP) were considered for inclusion. Inclusion and exclusion criteria are shown in Tables 1 and 2 ,  respectively. Potential candidates were screened for eligibility and underwent baseline assessments including history, physical examination, radiological studies, concomitant medications, vital signs, drug-screening test, pregnancy test (where applicable), tuberculin skin test, and laboratory tests (serum hematology, coagulation studies, chemistry, urinalysis) 3 to 14 days before administration of the fi rst dose.
Randomization
One computer-generated randomization schedule was prepared before the start of the study and used across all sites. When notifi ed that a subject had completed the screening period, the investigational pharmacist requested the next available randomization number in sequence and matched this number to the master randomization list and then prepared the assigned study treatment for that subject.
Subjects were randomized in a 1:1:1:1 block manner to 1 of 3 doses of etanercept (0.5, 2.5, 12.5 mg) or placebo, with 10 subjects in each cohort. Subjects who were withdrawn from the study or who were not evaluable per protocol (PP) because of a major protocol deviation were replaced with the replacement subject being allocated the same treatment dose level as the withdrawn or nonprotocol subject.
Blinding
All subjects, clinicians performing transforaminal injections, radiologists reading postinjection fi lms, postinjection evaluators, statisticians, and study personnel remained blinded to treatment until after database lock, except those persons responsible for the packaging and distribution of the trial medications and the biostatistician preparing the random code.
After randomization, each subject received 2 consecutive injections (etanercept or placebo), 2 weeks apart, of the same "treatment" and dose. Doses of etanercept or placebo were administered at study week 2 and 4, with follow-up visits at study week 6, 8, 12, 16, and 28 (2, 4, 8, 12 , and 26 weeks after the second injection, respectively).
Subjects maintained a study diary as a daily record of pain levels, concomitant medication use, and AEs during the full 3. Subject has a mean score of at least 5/10 for "average leg pain during the past 24 hr" more than 3 to 7 d before the randomization visit.
4. Subject has a "current" diagnosis of lumbosacral radicular pain of between 6 and 26 wk of duration.
5. Pain must radiate into the leg in a dermatomal/myotomal distribution consistent with the suspected involved nerve root and the diagnosis of lumbosacral radicular pain.
6. Diagnosis must be confi rmed by CT or MRI related to the symptoms present at screening with this investigation being performed within a maximum of 6 mo before the screening visit. This study should demonstrate disc herniation at a location consistent with the clinical symptoms of radicular pain and nerve root irritation.
7. At least one of the after: positive straight leg raise (L5, S1), positive femoral stretch test (L3, L4) or other positive test upon physical examination that is consistent with the presence of sciatic nerve root irritation at screening.
8. Disc herniation must affect the L3, L4, L5, or S1 nerve root. 4. Subject has a HADS score > 10 on either subscale or has an established history of major psychiatric disorder not controlled with medication.
5. Subject has clinically signifi cant abnormalities in clinical chemistry, hematology or urinalysis, including serum glutamic-oxaloacetic transaminaseAST or serum glutamic-pyruvic transaminase/ALT ≥ 2 times the upper limit of the reference range or a creatinine clearance < 70 mL/min (Cockcroft Gault formula) at screening.
6. Subject has signifi cant pain unrelated to the disc herniation (in addition to radicular buttock or leg pain related to the disc herniation).
7. Subject has clinical evidence of radicular pain at "more than" 1 spinal nerve.
8. Subject has received any investigational drug within 30 d before screening, or is scheduled to receive an investigational drug, other than blinded-study drug during the course of this study.
9. Subject has had lumbar or sacral back surgery related to the specifi c disc that is the cause of the sciatic pain upon presentation to the study, or currently plans to undergo spine surgical intervention while in the study.
10. Subject has received epidural corticosteroid injections in the back "within 6 mo" of screening.
11. Subject is involved in an ongoing worker's compensation claim, disability, or litigation related to any pain problem.
12. Any active infection or malignancy. study period. At each clinic visit, subjects were assessed for safety by review of AEs, and for effi cacy by in-clinic collection of diary cards, assessment of pain, and completion of questionnaires regarding pain and quality of life.
History of chronic infection, tuberculosis, HBV, HCV, HIV or diabetes that is either: (

Transforaminal Epidural Injection
After application of skin preparation, 2 mL of 1% plain lignocaine was injected into the skin surface at the point of planned injection. Using a 22-gauge 3.5-in needle, the relevant foramen was targeted via a posterolateral approach (for L3, L4, L5) ( Figure 1 ) or a direct posterior approach (for S1) ( Figure 2 ). Once the needle tip was in the ideal position, and after a negative cerebrospinal fl uid aspiration, a maximum of 2.0 mL of nonionic contrast media (Iohexol-180, Amersham Health, Oslo, Norway) was injected. Once the operator confi rmed satisfactory fl ow of contrast in the anteroposterior, lateral (and oblique if required) and after a further negative cerebrospinal fl uid aspiration, the 2.0 mL of injectate allocated to the subject was injected slowly for 2 minutes. All patients had pulse and blood pressure checked every 15 minutes for 1 hour and hourly thereafter for a total of 4 hours. A neurological examination was performed before discharge. All radiographical images (anteroposterior, lateral, and oblique) of the fi nal needle-tip position and subsequent contrast fl ow were reviewed in a blinded fashion by an expert independent reader within 24 hours to confi rm satisfactory needle placement and epidural contrast fl ow.
Outcomes Assessments
The prespecifi ed primary effi cacy endpoint was the difference between each treated cohort and the placebo cohort for average change in mean daily worst leg pain (WLP) comparing scores at baseline to 4 weeks after the second injection. The secondary effi cacy endpoints included average change from baseline in mean daily WLP, ALP, worst back pain (WBP), average back pain (ABP), in-clinic pain assessment, ODI, and patient global impression of change at each postdose visit. Safety monitoring included vital signs, physical examination, and treatment-emergent adverse events (TEAEs).
Statistical Methods
Sample size was calculated using data from Cohen et al . 13 These authors reported a mean numerical rating leg pain score of 6.3 at baseline with a standard deviation of 1.6 in a cohort of 24 subjects with subacute lumbosacral radiculopathy. 13 The minimal clinically important difference of the visual analogue scale score for back/leg pain has previously been reported as 2.0. 14 For this study, the risk of a type I error was set at 10% ( P < 0.10) and the risk of a type II error was set at 20% (equating to a power = 80%). The estimated sample size was calculated with n = 10 for each group and a total sample size of N = 40. The prespecifi ed level for statistical signifi cance was set P < 0.1. This level was selected on the basis of the stage of the study (phase IIa), the size of the study and the expected treatment effect size and designed to detect a potential signal of effi cacy in a small group of subjects.
Subjects were enrolled until 40 subjects were confi rmed to have reached visit 5. The primary effi cacy variable was summarized in terms of descriptive statistics by treatment. Treatments were compared using a linear model with treatment as a fi xed effect and baseline pain score as a covariate. Pairwise contrasts of interest were primarily the etanercept doses (0.5 mg, 2.5 mg, and 12.5 mg) compared with placebo. The primary prespecifi ed comparisons identifi ed in the earlier text adjusted the P values for multiple comparisons using the Benjamini-Hochberg method. Similar methods were used in analyzing the secondary effi cacy variables.
The intention-to-treat (ITT) population included all subjects who received any planned study medication after randomization. The PP population included all subjects who received both doses of study medication with independent confi rmation of epidural needle placement and contrast fl ow for the fi rst and second injections and who t at least one pain assessment after the second injection (week 4) visit. The PP population excluded all subjects with protocol deviations and forms the basis for all primary analyses. The safety population included all subjects who received any amount of planned study medication (analyzed as treated). Safety and tolerability data were summarized by treatment group using appropriate descriptive statistics.
Continuous variables were summarized with mean, median, standard deviation, and minimum and maximum values, whereas discrete variables were summarized using number and percentage for each category. Confi dence intervals when appropriate were provided at the 90% level for key effi cacy variables.
RESULTS
A total of 156 subjects were screened for inclusion in the study. Fifty-one subjects were recruited and randomized, with 49 subjects receiving both transforaminal injections ( Figure 3 ). The number of subjects enrolled by site is shown in Table 3 . Six subjects did not complete the study. Two subjects withdrew to undergo treatments for sciatica not permitted under the protocol (1 nonpermitted medication, 1 nonpermitted epidural steroid injection). Four subjects were withdrawn because of AEs (n = 2 for worsening of sciatica; n = 2 for recurrence of radicular pain). Both subjects withdrawing for radicular pain were included in the PP analysis set because withdrawal occurred after week 6. Two subjects received low volume in 1 of the 2 injections (inadequate dose). For 8 subjects, independent reader review of the fl uoroscopy images of the epidural injections failed to confi rm appropriate epidural contrast fl ow at the affected spinal nerve root. In total, 12 subjects were excluded from the effi cacy analysis because of protocol violation. The treatment groups were well matched with respect to baseline characteristics for the PP population including demographics, duration, and severity of radicular symptoms ( Table 4 ) .
Effi cacy Evaluation
The safety population and the ITT population were the same population of 49 subjects. The PP population included 37 subjects and provided the key data set for analyses of primary and secondary effi cacy endpoints.
The decrease from baseline in mean daily WLP score for the etanercept 0.5-mg group was 4.4 (ITT) and 5.1 (PP) versus a decrease of 1.8 (ITT) and 1.9 (PP) in the placebo group ( Table 5 ) . This difference in outcome was clinically and statistically signifi cant ( P < 0.1) for the 0.5-mg treatment group compared with the placebo group in both the ITT November 2013
( P = 0.058) and PP ( P = 0.066) populations. The etanercept 2.5-mg and 12.5-mg treatment groups also demonstrated reduction in mean daily WLP scores compared with placebo ( Figure 4 ) . Although the reduction in these 2 groups was not statistically signifi cant when compared with placebo, the pain scores in each drug-treatment group were reduced to a greater extent than seen in the placebo group. Responder rates evaluate the percentage of subjects in each group who show a specifi ed pain response. Fifty percent of subjects in the etanercept 0.5-mg group reported a 100% reduction in the mean daily WLP scores to mean daily WLP scores of zero at 4 weeks post-treatment, whereas no subjects in the placebo group reported a 100% reduction. This difference was clinically and statistically signifi cant.
Clinically and statistically signifi cant changes in mean daily ALP ( Figure 5 ), WBP ( Figure 6 ), and ABP ( Figure 7 ) were observed for the 0.5-mg etanercept group compared with placebo. Mean daily WBP and ABP were also reduced to a clinically and statistically signifi cant degree in the 2.5-mg etanercept cohort and 12.5-mg etanercept cohort when compared with placebo.
The 0.5-mg etanercept group showed a statistically significant reduction in mean ODI from baseline and also percent ODI change from baseline to week 4. Three months after treatment, the 0.5-mg group consistently maintained at least a 10-point greater change from baseline than the placebo group, and also a percentage reduction at least 30 percentage points greater than that observed in the placebo group. The percentage of subjects rating their well-being with patient global impression of change as signifi cantly improved was 63% for the etanercept 0.5-mg group, 30% for etanercept 2.5-mg group, 11% for etanercept 12.5-mg group, and 10% for placebo group.
Safety Evaluation
The overall incidence of AEs in the etanercept treated subjects (59%) was similar to that in the placebo group (67%). The rates in the 3 drug-treatment groups (38% to 88%) clustered around the incidence rate seen in the placebo group (67%), with no consistent dose relationship observed. Commonly occurring AEs included sciatica, headache, nausea, diarrhea, and constipation. Although there was no clear dose-related trend in the incidence of most of these commonly occurring AEs, the possibility of elevated incidence and severity of sciatica in the 12.5-mg etanercept group cannot be ruled out. Most of the total of 100 AEs were classifi ed as mild (N = 66) or moderate (N = 24), with 10 classifi ed as severe (6 worsening sciatic pain, 2 recurrent lumbar radiculopathy, 1 headache, and 1 irregular heart beat). Most study discontinuations occurred in subjects who had grade 3 AEs of increased sciatic pain. In total, 5 from 49 subjects (10.2%) underwent discectomy surgery within the 6-month follow-up period. The percentage of patients undergoing this surgery was similar among the groups (1 subject from the placebo group, 1 from 0.5-mg etanercept group, 1 from the 2.5-mg group, and 2 from the 12.5-mg group).
DISCUSSION
Persistent moderate to severe leg pain is the most bothersome aspect for patients with radicular pain, contributing to pain burden, disability, decreased quality of life, and progression to surgery. This study achieved its prespecifi ed primary efficacy endpoint by demonstrating a clinically and statistically signifi cant reduction of mean daily WLP 4 weeks after treatment with 2 transforaminal injections of the TNF-α inhibitor etanercept. In addition, a clinically and statistically signifi cant difference between the 0.5-mg etanercept and placebo cohorts was consistently seen across mean daily ALP, and mean daily WBP and ABP when compared with the placebo in the PP population. Results for the ITT population were similarly supportive of a therapeutic effect, with more variation in dose effect. These fi ndings suggest that 2 transforaminal injections of 0.5 mg of etanercept provided substantial rapid reduction in WLP for the majority of treated subjects, persisting for 6 months after treatment.
Although WLP is the most bothersome aspect of radicular pain, and also the most sensitive to measurement of intervention, ALP is more refl ective of the overall pain burden for the subject. The 0.5-mg etanercept cohort showed a reduction in ALP similar in magnitude and signifi cance to the reduction in WLP. The etanercept treated groups also showed signifi cant reductions in mean daily WBP and mean daily ABP 4 weeks after the second etanercept injection and were maintained for at least 3 months. These results suggest that epidural etanercept can reduce both radicular pain and back pain. Patients undergoing discectomy for lumbar disc herniation often report a prompt reduction in leg pain, but many complain of persistent or in some cases worse low back pain after surgery. 15 In this study, etanercept at the 0.5-mg dose produced impressive reductions both in WBP and ABP out to 6 months.
The observed responder rates and improvement in mean ODI in the 0.5-mg etanercept group suggest that etanercept treatment can reduce disability by a clinically meaningful extent within 2 weeks of treatment and persisting for at least 3 months after the treatment. The observation that 2 weeks after the fi rst injection, more than 63% of the 0.5-mg group, but only 10% of the placebo group, rated themselves as very much improved or much improved, suggests that the treatment not only affected pain scores, but also the subjects' overall impression of recovery and well-being.
In this study, the lowest dose of etanercept (0.5 mg) was the most effective in reducing WLP and WBP. This fi nding is consistent with the results of a previously published study of epidural etanercept, where the lowest dose of etanercept (2 mg) was more effective than either the 4-mg or the 6-mg dose, accepting that the numbers in the previous study were small. 13 Reverse-dose effects are not unusual in biological systems; one such effect has been reported with off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion resulting in osteolysis rather than bony fusion. 16 In this case, it has been suggested that osteolysis may be the result of supraphysiological doses of the osteoinductive agent. One possible explanation for the higher doses of etanercept being less effi cacious in our study could be that the higher doses, through TNF inhibition, in some way inhibit macrophage-mediated disc resorption. This would need to be explored in larger trials with greater power and a wider dose range, requiring more preclinical safety data before dosing.
Cohen et al 17 recently reported a randomized trial in 84 patients with lumbosacral radiculopathy of less than 6 months duration. Subjects received 2 epidural injections of corticosteroids, etanercept (4 mg) or saline, mixed with bupivicaine. A greater reduction in leg pain 1 month after the second injection was observed with corticosteroids than etanercept or saline. There are important differences between the Cohen study and the study presented here. The study by Cohen et al 17 was less rigorous, for example, including participants with herniated discs or annular tears, mean improvement in visual analogue scale scores for leg pain postintervention were modest ( − 1.26 to − 0.52) for all groups and not statistically signifi cant. Differences in back pain and function associated with steroids versus saline also were also not statistically signifi cant.
CONCLUSION
This randomized, double-blind, placebo-controlled trial has provided support for the hypothesis that transforaminal epidural etanercept is safe and effective (0.5-mg dose), with the potential to provide signifi cant therapeutic relief for patients with persistent sciatica via a brief widely available nonoperative outpatient procedure.
This study was a phase IIa clinical trial. Such studies typically focus on type of patient, dose response, and the frequency of dosing as well as safety and effi cacy. A signal of effi cacy has been identifi ed suggesting potential for transforaminal epidural etanercept in this patient cohort. This study provides valuable information regarding safety, patient population, dosing , effect size, and variability to assist with the design of larger phase III confi rmatory trials.
➢ Key Points
In this RCT, two transforaminal injections of the TNFα inhibitor etanercept provided statistically and clinically signifi cant reductions in mean daily worst leg pain compared to the placebo for patients with persistent sciatica. Transforaminal epidural etanercept (0.5 mg) provided 50-100% relief of pain for at least 3-6 months for more than one-half of subjects with persistent moderate to severe sciatica secondary to lumbar disc herniation. Clinically and statistically signifi cant improvements were also noted in worst leg pain worst back pain, average back pain, and Oswestry disability index in etanercept-treated patients when compared to the placebo cohort. There was no diff erence in the incidence of adverse events in the etanercept cohorts when compared to the placebo cohort. Epidural etanercept could off er sciatica patients a safe and eff ective non-operative treatment.
